GoAI
Get started
Outset Medical, Inc. logo

Outset Medical, Inc.

OM

NASDAQHealthcareMedical - Devices

Open in GoAI

Latest quote

$4.20

−$0.09 · -2.09%

Aug 21, 3:55 PM ET

OM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

65

Undervalued

Momentum

26

Weakening

Sentiment

51

Mixed

Risk resilience

20

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Leslie L. Trigg
Listed since
Sep 15, 2020
Employees
310

Market position

Volume
150.99K
0.77× average
Average volume
196.87K
Average daily volume
Market cap
78.04M USD
Beta
1.92
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
122.67M USD
EV / EBITDA
-1.97×
Earnings yield
-144.69%
Free cash flow yield
-83.51%

Profitability & efficiency

Return on equity
-64.32%
Return on assets
-30.87%
Return on invested capital
-29.18%

Financial health

Current ratio
6.67×
Altman Z-score
-6.07
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends57%-15%-87%-159%Gross margin, FY2021: 7.42%Gross margin, FY2022: 15.46%Gross margin, FY2023: 22.24%Gross margin, FY2024: 33.92%Gross margin, FY2025: 39.13%Operating margin, FY2021: -127.21%Operating margin, FY2022: -139.56%Operating margin, FY2023: -130.22%Operating margin, FY2024: -99.72%Operating margin, FY2025: -55.84%Net margin, FY2021: -128.59%Net margin, FY2022: -141.24%Net margin, FY2023: -132.54%Net margin, FY2024: -112.57%Net margin, FY2025: -68.34%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 7.42%. Gross margin FY2022 15.46%. Gross margin FY2023 22.24%. Gross margin FY2024 33.92%. Gross margin FY2025 39.13%. Operating margin FY2021 -127.21%. Operating margin FY2022 -139.56%. Operating margin FY2023 -130.22%. Operating margin FY2024 -99.72%. Operating margin FY2025 -55.84%. Net margin FY2021 -128.59%. Net margin FY2022 -141.24%. Net margin FY2023 -132.54%. Net margin FY2024 -112.57%. Net margin FY2025 -68.34%.

Income trends

Revenue

119.48M USD+5.09%

Operating income

−66.71M USD+41.16%

Net income

−81.65M USD+36.20%
Income trends across reported periods160.69M USD39.42M USD−81.85M USD−203.11M USDRevenue, FY2021: 102.6M USDRevenue, FY2022: 115.38M USDRevenue, FY2023: 130.38M USDRevenue, FY2024: 113.69M USDRevenue, FY2025: 119.48M USDOperating income, FY2021: −130.52M USDOperating income, FY2022: −161.02M USDOperating income, FY2023: −169.77M USDOperating income, FY2024: −113.38M USDOperating income, FY2025: −66.71M USDNet income, FY2021: −131.94M USDNet income, FY2022: −162.96M USDNet income, FY2023: −172.8M USDNet income, FY2024: −127.98M USDNet income, FY2025: −81.65M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 102.6M USD. Revenue FY2022 115.38M USD. Revenue FY2023 130.38M USD. Revenue FY2024 113.69M USD. Revenue FY2025 119.48M USD. Operating income FY2021 −130.52M USD. Operating income FY2022 −161.02M USD. Operating income FY2023 −169.77M USD. Operating income FY2024 −113.38M USD. Operating income FY2025 −66.71M USD. Net income FY2021 −131.94M USD. Net income FY2022 −162.96M USD. Net income FY2023 −172.8M USD. Net income FY2024 −127.98M USD. Net income FY2025 −81.65M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue119.48M USD113.69M USD130.38M USD115.38M USD102.6M USD
Cost of goods sold72.72M USD75.13M USD101.38M USD97.54M USD94.99M USD
Gross profit46.75M USD38.56M USD29M USD17.83M USD7.61M USD
Research and development21.24M USD38.4M USD57.31M USD48.86M USD36.74M USD
Selling, general, and administrative92.23M USD113.54M USD141.46M USD130M USD101.39M USD
Operating expenses113.46M USD151.94M USD198.77M USD178.85M USD138.13M USD
Interest income7.41M USD9.76M USD10.17M USD3.29M USD498K USD
Interest expense13.95M USD23.87M USD12.68M USD3.57M USD1.72M USD
Depreciation and amortization4.34M USD5.73M USD5.81M USD6.28M USD5.16M USD
Operating income−66.71M USD−113.38M USD−169.77M USD−161.02M USD−130.52M USD
Net income−81.65M USD−127.98M USD−172.8M USD−162.96M USD−131.94M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$14.00

232.54% upside
Past 12 months12-month forecastHigh $34.00Average $14.00Low $6.00

OM news

zacks.com

Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock

Outset Medical (OM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable…

Read source
seekingalpha.com

Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript

Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Outset Medical Q2 Earnings Call Highlights

Outset Medical NASDAQ: OM reported second-quarter 2026 revenue of $31.6 million, up 1% from a year earlier and 14% sequentially, as the dialysis technology company cited commercial progress, improving margins and a new…

Read source
zacks.com

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.84 per share a year ago.

Read source
globenewswire.com

Outset Medical Reports Second Quarter 2026 Results

SAN JOSE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and…

Read source
gurufocus.com

Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 29, 20

Read source

OM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding OM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.53M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
943.89K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
252.53K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
159.87K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
Fidelity Disruptive Medicine ETF logoFidelity Disruptive Medicine ETFFMED
Market value
146.2K
Weight
0.28%
AUM
45.46M USD
Expense ratio
0.50%
Price / 1D
$32.5289+1.43%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
114.96K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
104.62K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61+0.46%
Dimensional - US Sustainability Core 1 ETF logoDimensional - US Sustainability Core 1 ETFDFSU
Market value
28.84K
Weight
0.00%
AUM
2.35B USD
Expense ratio
0.15%
Price / 1D
$48.20+0.52%

Continue in GoAI

Research OM

research.disclaimer